ArticleChemical communications (Cambridge, England)2017
Novel bis-cyclic guanidines as potent membrane-active antibacterial agents with therapeutic potential.
Article in Chemical communications (Cambridge, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 44 citations in OpenAlex.
- Hydantoin derivative dimers as broad-spectrum antimicrobial agents against ESKAPE pathogens with enhanced killing rate and stability.RSC medicinal chemistry · 2024Article
- Recent Advances in Amphipathic Peptidomimetics as Antimicrobial Agents to Combat Drug Resistance.Molecules (Basel, Switzerland) · 2024Review
- Polyheterocyclic peptidomimetics: Parallel solid phase synthesis of oligo cyclic guanidines and their inhibition activity against Mycobacterium tuberculosis DNA gyrase.Bioorganic & medicinal chemistry letters · 2023Article
- Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?Frontiers in immunology · 2022Review
- Development of a Promising Method for Producing Oligomeric Mixture of Branched Alkylene Guanidines to Improve Substance Quality and Evaluate Their Antiviral Activity against SARS-CoV-2.Molecules (Basel, Switzerland) · 2021Article
- Dimeric lipo-α/sulfono-γ-AA hybrid peptides as broad-spectrum antibiotic agents.Biomaterials science · 2021Article
- Development of Bis-cyclic Imidazolidine-4-one Derivatives as Potent Antibacterial Agents.Journal of medicinal chemistry · 2020Article
- N-Terminal guanidine derivatives of teicoplanin antibiotics strongly active against glycopeptide resistant Enterococcus faecium.The Journal of antibiotics · 2020Article
- Challenges in the development of next-generation antibiotics: opportunities of small molecules mimicking mode of action of host-defense peptides.Expert opinion on therapeutic patents · 2020Article
- Antibacterial activity of lipo-α/sulfono-γ-AA hybrid peptides.European journal of medicinal chemistry · 2020Article
- Dimeric γ-AApeptides With Potent and Selective Antibacterial Activity.Frontiers in chemistry · 2020Article
- Polymyxin derivatives as broad-spectrum antibiotic agents.Chemical communications (Cambridge, England) · 2019Article
- Small AntiMicrobial Peptide With in Vivo Activity Against Sepsis.Molecules (Basel, Switzerland) · 2019Article
- Bis-Cyclic Guanidines as a Novel Class of Compounds Potent against Clostridium difficile.ChemMedChem · 2018Article
- A Novel Class of Cationic and Non-Peptidic Small Molecules as Hits for the Development of Antimicrobial Agents.Molecules (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
We designed a class of small dimeric cyclic guanidine derivatives which display potent antibacterial activity against both multidrug-resistant Gram-negative and Gram-positive bacteria. They could compromise bacterial membranes without developing resistance, inhibit biofilms formed by E. coli, and exhibit excellent in vivo activity in the MRSA-infected thigh burden mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.